Stock Analysis

Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

It's shaping up to be a tough period for Quanterix Corporation (NASDAQ:QTRX), which a week ago released some disappointing second-quarter results that could have a notable impact on how the market views the stock. It definitely looks like a negative result overall with revenues falling 18% short of analyst estimates at US$24m. Statutory losses were US$0.77 per share, 89% bigger than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

earnings-and-revenue-growth
NasdaqGM:QTRX Earnings and Revenue Growth August 10th 2025

After the latest results, the four analysts covering Quanterix are now predicting revenues of US$130.4m in 2025. If met, this would reflect a modest 3.6% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 15% from last year to US$1.25. Before this latest report, the consensus had been expecting revenues of US$131.6m and US$1.60 per share in losses. Although the revenue estimates have not really changed Quanterix'sfuture looks a little different to the past, with a very favorable reduction to the loss per share forecasts in particular.

Check out our latest analysis for Quanterix

The average price target held steady at US$10.75, seeming to indicate that business is performing in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Quanterix at US$18.00 per share, while the most bearish prices it at US$6.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Quanterix's revenue growth is expected to slow, with the forecast 7.4% annualised growth rate until the end of 2025 being well below the historical 9.9% p.a. growth over the last five years. Compare this to the 64 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 6.0% per year. Factoring in the forecast slowdown in growth, it looks like Quanterix is forecast to grow at about the same rate as the wider industry.

Advertisement

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at US$10.75, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Quanterix going out to 2027, and you can see them free on our platform here..

Before you take the next step you should know about the 3 warning signs for Quanterix that we have uncovered.

Valuation is complex, but we're here to simplify it.

Discover if Quanterix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:QTRX

Quanterix

A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

Flawless balance sheet and slightly overvalued.

Advertisement